Kubient, Inc.: Nasdaq/NYSE listing notice — Kubient receives Nasdaq notice for late Form 10-Q filing; has until Oct 21 to submit compliance plan

Kubient, Inc.

Received Nasdaq notice on Aug 22, 2023 for failure to timely file Q2 2023 Form 10-Q, violating Listing Rule 5250(c)(1).
Delay attributed to auditor not completing review of the Form 10-Q for the quarter ended June 30, 2023.
Company has 60 calendar days (until Oct 21, 2023) to submit a plan to regain compliance; possible exception to Feb 20, 2024.
Kubient continues working with auditor to complete the Form 10-Q but cannot estimate the filing date.
Common stock (KBNT) and warrants (KBNTW) trade on Nasdaq; non-compliance risk could affect listing status.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Kubient, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

August 15, 2023, Kubient, Inc. (the “Company”) filed a Notification of Late Filing on Form 12b-25, indicating, among other things, that the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the “Form 10-Q”) would be delayed principally due to the Company’s auditor having not completed their review of the Form 10-Q for the period ended June 30, 2023. Because of the delayed filing of the Form 10-Q with the United States Securities and Exchange Commission (the “SEC”), the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market L

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001140361-23-041520

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.